• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原发性人乳头瘤病毒检测的前景与风险

Promise and Perils of Primary HPV Testing.

作者信息

Spencer Jennifer C, Wheeler Cosette M

机构信息

Department of Population Health, Dell Medical School, University of Texas at Austin, Austin, Texas.

Department of Internal Medicine, Dell Medical School, University of Texas at Austin, Austin, Texas.

出版信息

Cancer Epidemiol Biomarkers Prev. 2024 Aug 1;33(8):982-983. doi: 10.1158/1055-9965.EPI-24-0716.

DOI:10.1158/1055-9965.EPI-24-0716
PMID:39086313
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11292190/
Abstract

Cervical cancer screening has reduced morbidity and mortality in many countries, but efforts to optimize screening modalities and schedules are ongoing. Using data from a randomized trial conducted in British Columbia, Canada, in conjunction with a provincial screening registry, Gottschlich and colleagues demonstrated that the estimated risk for precancerous disease (cervical intraepithelial neoplasia grades 2 or worse) at 8 years following a negative human papillomavirus (HPV) test was similar to the current standard of care (Pap testing after 3 years). The study supports extending screening intervals for those with a negative HPV test beyond currently recommended 5-year intervals. In an ideal world, the resources saved through less frequent routine cervical screening could be redirected to increasing screening uptake and follow-up of abnormalities to improve equity in cervical cancer prevention. However, implementation of extending screening intervals remains less than straightforward in settings with fragmented healthcare systems that lack information systems to support patient call/recall, such as the United States. To achieve the full promise of primary HPV testing, stakeholders at every level must commit to identifying and addressing the diverse spectrum of barriers that undergird existing inequities in care access, appropriately resource implementation strategies, and improve health information systems. See related article by Gottschlich et al., p. 904.

摘要

宫颈癌筛查已在许多国家降低了发病率和死亡率,但优化筛查方式和时间表的工作仍在进行中。戈特施利希及其同事利用在加拿大不列颠哥伦比亚省进行的一项随机试验的数据,并结合省级筛查登记处的数据,证明了人乳头瘤病毒(HPV)检测呈阴性后8年时癌前疾病(宫颈上皮内瘤变2级或更严重)的估计风险与当前的标准护理(3年后进行巴氏试验)相似。该研究支持将HPV检测呈阴性者的筛查间隔延长至超过目前建议的5年间隔。在理想情况下,通过减少常规宫颈癌筛查频率节省下来的资源可以重新用于提高筛查参与率和对异常情况的随访,以改善宫颈癌预防方面的公平性。然而,在像美国这样医疗保健系统分散且缺乏支持患者呼叫/召回的信息系统的环境中,延长筛查间隔的实施仍并非易事。为了充分实现初级HPV检测的前景,各级利益相关者必须致力于识别和解决构成现有医疗服务获取不平等基础的各种障碍,适当地为实施策略提供资源,并改善健康信息系统。见戈特施利希等人的相关文章,第904页。

相似文献

1
Promise and Perils of Primary HPV Testing.原发性人乳头瘤病毒检测的前景与风险
Cancer Epidemiol Biomarkers Prev. 2024 Aug 1;33(8):982-983. doi: 10.1158/1055-9965.EPI-24-0716.
2
Evidence of Decreased Long-term Risk of Cervical Precancer after Negative Primary HPV Screens Compared with Negative Cytology Screens in a Longitudinal Cohort Study.纵向队列研究中,与细胞学阴性筛查相比,HPV 阴性初筛后宫颈癌前病变长期风险降低的证据。
Cancer Epidemiol Biomarkers Prev. 2024 Jul 1;33(7):904-911. doi: 10.1158/1055-9965.EPI-23-1587.
3
The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.英格兰原发性人乳头瘤病毒子宫颈筛查的临床效果和成本效益:通过三轮筛查对 ARTISTIC 随机试验队列进行的扩展随访。
Health Technol Assess. 2014 Apr;18(23):1-196. doi: 10.3310/hta18230.
4
Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test.人乳头瘤病毒检测呈阴性可消除未来患癌前病变和癌症的风险。
J Natl Cancer Inst. 2014 Jul 18;106(8). doi: 10.1093/jnci/dju153. Print 2014 Aug.
5
HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.HPV 检测与常规细胞学检查在宫颈癌筛查中的比较:ARTISTIC RCT 的长期随访。
Health Technol Assess. 2019 Jun;23(28):1-44. doi: 10.3310/hta23280.
6
Human papillomavirus testing versus cytology in primary cervical cancer screening: End-of-study and extended follow-up results from the Canadian cervical cancer screening trial.原发性宫颈癌筛查中人类乳头瘤病毒检测与细胞学检查的比较:加拿大宫颈癌筛查试验的研究结束及延长随访结果
Int J Cancer. 2016 Dec 1;139(11):2456-66. doi: 10.1002/ijc.30385. Epub 2016 Aug 30.
7
The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: A population-based study of opportunistic cervical screening in the United States.特定型别人乳头瘤病毒感染对宫颈癌前病变和癌症检出的影响:美国机会性宫颈筛查的基于人群研究。
Int J Cancer. 2014 Aug 1;135(3):624-34. doi: 10.1002/ijc.28605. Epub 2014 Apr 15.
8
The performance of human papillomavirus DNA detection with type 16/18 genotyping by hybrid capture in primary test of cervical cancer screening: a cross-sectional study in 10,669 Chinese women.人乳头瘤病毒 16/18 型基因分型杂交捕获法在宫颈癌筛查初筛中检测人乳头瘤病毒 DNA 的性能:10669 例中国女性的横断面研究。
Clin Microbiol Infect. 2018 Dec;24(12):1322-1327. doi: 10.1016/j.cmi.2018.02.027. Epub 2018 Mar 5.
9
Cost-effectiveness analysis of repeated self-sampling for HPV testing in primary cervical screening: a randomized study.重复自我采样用于初级宫颈癌筛查中 HPV 检测的成本效益分析:一项随机研究。
BMC Cancer. 2020 Jul 13;20(1):645. doi: 10.1186/s12885-020-07085-9.
10
Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland.一次人乳头瘤病毒 DNA 初筛检测中对癌前和癌性宫颈病变的检出率:芬兰的一项前瞻性随机试验。
BMJ. 2012 Nov 29;345:e7789. doi: 10.1136/bmj.e7789.

本文引用的文献

1
Evidence of Decreased Long-term Risk of Cervical Precancer after Negative Primary HPV Screens Compared with Negative Cytology Screens in a Longitudinal Cohort Study.纵向队列研究中,与细胞学阴性筛查相比,HPV 阴性初筛后宫颈癌前病变长期风险降低的证据。
Cancer Epidemiol Biomarkers Prev. 2024 Jul 1;33(7):904-911. doi: 10.1158/1055-9965.EPI-23-1587.
2
Variation in cervical cancer screening test utilization and results in a United States-based program.美国某项目中宫颈癌筛查检测利用和结果的差异。
Gynecol Oncol. 2024 May;184:96-102. doi: 10.1016/j.ygyno.2024.01.020. Epub 2024 Jan 31.
3
Racial and Ethnic Disparities in Cervical Cancer Screening From Three U.S. Healthcare Settings.美国三个医疗保健环境中的宫颈癌筛查中的种族和民族差异。
Am J Prev Med. 2023 Oct;65(4):667-677. doi: 10.1016/j.amepre.2023.04.016. Epub 2023 May 3.
4
Impact of HPV testing in opportunistic cervical screening: Support for primary HPV screening in the United States.HPV 检测在机会性宫颈癌筛查中的影响:支持美国进行初级 HPV 筛查。
Int J Cancer. 2023 Jul 1;153(1):83-93. doi: 10.1002/ijc.34519. Epub 2023 Apr 7.
5
Adherence to National Guidelines on Cervical Screening: A Population-Based Evaluation from a Statewide Registry.遵循国家宫颈癌筛查指南:基于全州登记处的人群评估
J Natl Cancer Inst. 2021 Aug 31;114(4):626-30. doi: 10.1093/jnci/djab173.
6
Summary of Current Guidelines for Cervical Cancer Screening and Management of Abnormal Test Results: 2016-2020.2016 - 2020年宫颈癌筛查及异常检测结果管理现行指南摘要
J Womens Health (Larchmt). 2021 Jan;30(1):5-13. doi: 10.1089/jwh.2020.8918.
7
Cervical cancer screening in the United States: Challenges and potential solutions for underscreened groups.美国的宫颈癌筛查:针对未充分筛查人群的挑战和潜在解决方案。
Prev Med. 2021 Mar;144:106400. doi: 10.1016/j.ypmed.2020.106400. Epub 2021 Jan 1.
8
HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.HPV 检测与常规细胞学检查在宫颈癌筛查中的比较:ARTISTIC RCT 的长期随访。
Health Technol Assess. 2019 Jun;23(28):1-44. doi: 10.3310/hta23280.
9
Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement.宫颈癌筛查:美国预防服务工作组推荐声明。
JAMA. 2018 Aug 21;320(7):674-686. doi: 10.1001/jama.2018.10897.